Prostate cancer management: 2. An update on locally advanced and metastatic disease.

Item

http://www.wikidata.org/entity/Q35599939

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Prostate cancer management: 2. An update on locally advanced and metastatic disease.

@ast

Prostate cancer management: 2. An update on locally advanced and metastatic disease.

@en

type

Item

label

Prostate cancer management: 2. An update on locally advanced and metastatic disease.

@ast

Prostate cancer management: 2. An update on locally advanced and metastatic disease.

@en

prefLabel

Prostate cancer management: 2. An update on locally advanced and metastatic disease.

@ast

Prostate cancer management: 2. An update on locally advanced and metastatic disease.

@en

P1476

Prostate cancer management: 2. An update on locally advanced and metastatic disease.

@en

P2093

Birtle AJ

http://www.w3.org/2001/XMLSchema#string

Bott SR

http://www.w3.org/2001/XMLSchema#string

Kirby RS

http://www.w3.org/2001/XMLSchema#string

Taylor CJ

http://www.w3.org/2001/XMLSchema#string

P2860

Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study

Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group.

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate.

Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.

Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89?

Prostate cancer management: (1) an update on localised disease

Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases.

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.

Treatment of clinical local failure after radiation therapy for prostate carcinoma.

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

P304

643-645

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1136/PMJ.79.937.643

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

937

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14654575

http://www.w3.org/2001/XMLSchema#string

P932

1742876

http://www.w3.org/2001/XMLSchema#string